Biopharmaceutical companies are accelerating phase II and phase III clinical trials for targeted mRNA oncology therapies designed for individual patient tumor profiles.
Personalized Antigen Selection
Next-generation sequencing enables researchers to identify patient-specific neoantigens within days, allowing rapid synthesis of therapeutic candidate batches.
Manufacturing Scale Considerations
Commercializing individualized mRNA therapies requires decentralized manufacturing hubs to deliver patient-specific doses within critical therapeutic windows.